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Background: Breast cancer remains a major health problem in the world. Triple-negative breast cancer 
(TNBC) is an aggressive subtype with very poor prognosis. Up to now, the mechanism behind TNBC’s 
activity is still unclear and no candidate drug target has been identified. Thus, it is of critical importance 
to elucidate the pathways in TNBC and identify the relevant biomarkers. Recent studies showed that 
ganglioside D3 synthase (GD3s) played a very important role in development of cancers. However, the 
physiological functions and associated pathways of GD3s in TNBC are still unclear. 
Methods: In silico analysis of the expression of GD3s in TNBC was conducted using The Cancer Genome 
Atlas (TCGA) and Oncomine databases. The proliferation of breast cancer cells was measured by MTT 
assay, colony formation by the soft agar method, and migration and invasion using Boyden chamber inserts. 
The methylation level of the gene encoding GD3s, ST8SIA1, in specimens was assessed by qMS-PCR and 
in silico using the UCSC gene browser. Protein expression was examined via immunohistochemistry (IHC), 
qRT-PCR and Western immunoblotting.
Results: In silico analysis showed a higher GD3s expression in ER− than ER+ breast cancers and GD3s was 
also highly expressed in TNBC compared to other types of breast cancers. The elevated GD3s expression 
in TNBC cells and tissues was associated with hypomethylation of the ST8SIA1 gene. Overexpression of 
GD3s in human breast cancer cells increased their proliferation, migration, invasion and colony formation 
ability. GD3s expression in breast cancers was closely associated with relapse-free survival (RFS) and overall  
survival (OS).
Conclusions: In summary, these results suggest that GD3s may be a potential biomarker and drug target 
in treatment of TNBC.
Keywords: Ganglioside D3 synthase (GD3s); triple-negative breast cancer (TNBC); biomarker; methylation; 
prognosis
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Introduction
Breast cancer has become the second most common cause 
of mortality and morbidity in women all over the world (1). 
Breast cancers have many subtypes, but there are three 
main ones: ER+, HER2+ and triple-negative breast cancer 
(TNBC) (2). TNBC is a very aggressive cell type with a 
poor prognosis. Understanding the molecular mechanism 
of TNBC malignancy should allow researchers to identify 
new effective drug targets.
Gangliosides are very important in the development (3), 
differentiation (4,5) and proliferation (6) of cells. Ganglioside 
D3 (GD3) and ganglioside D2 (GD2) are strongly 
expressed in neuroectoderm-derived cancers and thought 
to be important in the malignant transformation of tumor 
cells (7). The expression profiles of gangliosides in the 
development and transformation of many cancers have been 
determined (8,9). GD3 is highly expressed in malignant 
melanomas (10,11) where it can be used as a biomarker 
of human melanoma (12) since it is only expressed at low 
levels in normal melanocytes (13). GD2 is overexpressed in 
melanomas and small cell lung cancers where it increases 
the growth and invasiveness of cells (14). GD2 was used as 
a biomarker of breast stem cells (15) and mesenchymal stem 
cells (16).
GD3 synthase (GD3s) is one of six members of the 
ST8Sia subfamily of sialyltransferases (ST8Sia I-VI), also 
known as ST8SIA1. GD2 and GD3 are highly expressed 
in many malignant cancers (17-19) and GD3s is the 
only enzyme that is responsible for biosynthesis of GD2 
and GD3 (20). GD3s plays a very important role in the 
development of cancers (21,22), but the signaling pathways 
involved in GD3s activity in breast cancers like TNBC have 
not been fully delineated. 
In this study, we explored the expression of GD3s in 
cells and tissues of different types of breast cancer and 
found higher GD3s levels in ER− breast cancers than in ER+ 
breast cancers and a negative correlation with the signature 
of luminal breast cancer. GD3s overexpression in TNBCs 
was associated with hypomethylation of the synthase gene, 
ST8SIA1, and resulted in increased proliferation, invasion, 
migration and colony formation of cell. Inhibition of GD3s 
reduced proliferation, invasion, migration and colony 
formation of cell. Clinically, a lower GD3s expression was 
clearly associated with relapse-free survival (RFS) and 
increased overall survival (OS) of breast cancer patients.
Methods 
Cell culture
The human breast cancer cell lines, MCF-7, MDA-
MB-468 and T47D, were purchased from the American 
Type Culture Collection. MCF-7 cells were cultured in 
DMEM, while MDA-MB-468 and T47D were cultured in 
RPMI 1640. Both mediums were supplemented with 10% 
fetal calf serum, 100 units/mL penicillin, and 100 µg/mL 
streptomycin at 37 ℃ in a humidified incubator containing 
5% CO2.
Tumor specimens
The Institutional Review Board at the John Wayne Cancer 
Institute/Saint John Health Center Providence Health 
System, Santa Monica, CA, approved the use of human 
tissues (MORD-RTPCR-0995). Immunohistochemistry 
(IHC) was carried out on sections from paraffin-embedded 
archival tissue (PEAT) specimens of breast cancers, which 
had been diagnosed at the Saint John Health Center 
Providence Health System, Santa Monica, CA. 
Stable transfection
MCF-7 cells were seeded in 60 mm dishes at 70–80% 
confluence for 24 h before transfection. MCF-7 cells, 
which do not express GD3s, were transfected with a 
GD3s expression plasmid using the transfection reagent, 
Lipofectamine™ 3000, (Invitrogen, Grand Island, NY, 
USA) for 24 h. The cells were then grown in the presence of 
800 µg/mL G418 (Invitrogen, Grand Island, NY, USA) for 
three weeks. MCF-7 cells with high GD3s expression were 
referred to as MCF-7-GD3s. MDA-MB-468 cells, which 
have a normally high GD3s expression level, were plated 
in 60 mm dishes at 70–80% confluence for 24 h before 
transfection with GD3s shRNA (Sigma-Aldrich, St. Louis, 
MO, USA). Stably transfected MDA-MB-468-shRNA cells 
were selected by incubation with 5 µg/mL puromycin. For 
controls, MCF-7 cells were transfected with empty vector 
(MCF-7-cntl) and MDA-MB-468 cells were transfected 
with a control shRNA (MDA-MB-468cntl).
GD3s expression was verified by Western blotting 
with anti-GD3s antibody (Abcam, Cat. No. ab214936, 
Cambridge, UK), anti-myc antibody (EMD Millipore, 
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Cat. No. 06-340, San Diego, CA) and anti-FLAG antibody 
(Origene, Cat. No. TA50011-100, Rockville, MD, USA).
Cell growth and colony formation in soft agar
Cell proliferation was assessed by MTT [3-(4,5-dimethylthiazol-2-
yl)-2,5 diphenyltetrazolium] assay (Sigma-Aldrich, St. Louis, 
MO, USA). The colony formation assay in soft agar was 
carried out in six-well culture plates. After 2–3 weeks, the 
colony were stained with 5 mg/mL MTT and the number 
was counted. Each experiment was done in triplicate.
Cell migration and invasion assay
About 1×104 cells were seeded on top of the Boyden 
chamber inserts (BD Biosciences, San Jose, CA, USA) and 
10% fetal calf serum was used as the chemoattractant. To 
reduce the effect of cell proliferation, mitomycin C was 
added to the cells to a final concentration of 2 µg/mL. 
Cells that had migrated through the membrane onto the 
lower surface of the inserts were stained with 1% crystal 
violet and counted in four randomly selected fields using a 
microscope. For invasion assays, inserts were coated with 
a thin layer of Matrigel basement membrane matrix. The 
subsequent steps in the invasion assay were the same as 
those of the migration assay.
In silico analysis
The Oncomine database (www.oncomine.org) is very useful 
for investigating genes that are expressed in multiple cancer 
datasets to validate the relationship between transcription 
and disease. More advanced analyses were used to 
check gene expression in a small fraction of samples of a 
cancer type using different filters. The expression of GD3s 
mRNA was checked in the subtypes of breast cancers. 
The Cancer Genome Atlas (TCGA) was initiated by the 
National Cancer Institute (NCI) and the National Human 
Genome Research Institute (NHGRI) and can be utilized to 
study the molecular basis of cancer through the application 
of genome analysis technologies. The cBioPortal for Cancer 
Genomics (http://www.cbioportal.org/) provides many 
different cancer data sets, such as sequencing data, 
microarray data, RNA-Seq data, etc. The cBioPortal can 
also be used to assess the effects of co-expression of genes. 
There is a data set of 1,881 breast tumor samples and a 
51-sample breast cancer cell line set available in GOBO 
(http://co.bmc.lu.se/gobo). Many different analyses can 
be performed using these data sets, which were all from 
Affymetrix U133A microarrays. The mRNA expression of 
specific genes in cancers can be easily checked in GOBO. 
The association between gene expression and patient 
outcomes can also be determined by using the GOBO 
dataset. The website (https://genome-cancer.ucsc.edu/proj/
site/hgHeatmap/) was used to assess the methylation of 
genes in different cancers from TCGA data.
Quantitative reverse transcriptase-PCR (qRT-PCR)
Total RNA (1 µg) was extracted from breast cancer cell 
lines and used for cDNA synthesis according to the 
manufacturer’s instructions. (Qiagen, Hilden, Germany). 
The cDNA was added to PCR mixture that contained 
1X SYBR Green PCR master mix (Quanta Biosciences, 
Gaithersburg, MD) and 300 nmol/L gene-specific GD3s 
primers (AuGCT). The assays were carried out three times 
on a CFX thermocycler (Bio-Rad, Hercules, CA). The 
primers are given in Table 1.
Quantitative real-time methylation-specific PCR  
(qMS-PCR)
Genomic DNA was extracted from MCF-7 and T47D 
breast cancer cells (1×106) using a QIAamp DNA Mini Kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s 
protocol. The bisulfite DNA modification was performed 
according to the manufacturer’s instructions and the 
methylation level of the ST8SIA1 gene was determined 
by qMS-PCR using two primer sets, one designed for 
methylated (M) DNA and the other for unmethylated 
(U) DNA. The primers for the methylation-specific PCR 
and unmethylated-specific PCR of the ST8SIA1 gene 
Table 1 Primers for qRT-PCR
Primer Forward Reverse
GD3s ACGGCGTGGAGGAGGAAC CAAAGGAGGGAGATTGCATCG
qRT-PCR, quantitative reverse transcriptase-PCR.
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(Table 2) were designed using Urogene’s MethPrimer 
software: (http://www.urogene.org/cgi-bin/methprimer/
methprimer.cgi).
 
IHC
IHC was carried out on five-micron sections from PEAT 
specimens. Expression of GD3s protein was measured using 
polyclonal anti-GD3s rabbit antibody (No. HPA026775, 
Sigma-Aldrich, St. Louis, MO, USA) at a dilution of 
1:200. Slides were deparaffinized, then rehydrated and 
washed in 1X PBS. Antigen retrieval was done with citrate 
buffer (Sigma-Aldrich) at 100 ℃ for 10 min. After antigen 
retrieval, slides were incubated in 3% H2O2 (Sigma-Aldrich) 
to block endogenous peroxidase at room temperature. 
The GD3s antibody was added to the slides, which were 
incubated overnight at 4 ℃, followed by 1 h incubation 
with biotinylated second Ab. Staining was done with 
diaminobenzidine (Vectastain, Burlingame, CA, USA) and 
cells were counterstained with hematoxylin (Sigma-Aldrich). 
The negative controls were treated with rabbit serum alone 
(Santa Cruz Biotechnology, Dallas, TX, USA). A Nikon 
Eclipse Ti microscope was used to take photograph of 
stained sections and staining density was analyzed by Image 
J software (http://rsbweb.nih.gov/ij/). 
Western immunoblotting
Western immunoblotting analysis was done as previously 
described (23). Cells were lysed in RIPA buffer on ice with 
protease inhibitors (Applygen Technologies Inc., Beijing, 
China) and total protein was extracted. Protein lysates 
were separated on 12% polyacrylamide gels with SDS-
Tris-glycine running buffer, transferred to polyvinylidene 
difluoride (PVDF) membranes, and blocked with 5% milk 
in TBST. The PVDF membranes were then incubated 
overnight with primary antibodies for GD3s (Abcam, No. 
ab37806, Cambridge, UK) and GAPDH (No. 10494-1-AP, 
Proteintech, Wuhan, China). After washing with TBST, 
the blots were incubated with HRP-conjugated secondary 
antibodies (No. 7074, anti-rabbit IgG; No. 7076, anti-
mouse IgG, Cell Signaling Technology, Danvers, USA). 
Signal detection was performed using the Pierce™ ECL 
Western blotting substrate (Thermo Fisher Scientific, 
Waltham, MA, USA) and Bio-Rad Imaging System 
(Hercules, USA).
Statistical analysis 
The results are given as mean ± SD. Statistical significance 
between different group was assessed by Student’s t-test. A 
P<0.05 was considered to be statistically significant.
Results 
GD3s was inversely associated with signature biomarkers 
of luminal breast cancers: ESR1, FOXA1, GATA3, XBP1 
and MYB
To explore the association between GD3s and the 
biomarkers of luminal breast cancers, we downloaded and 
analyzed the co-expression data for GD3s from TCGA 
(http://www.cbioportal.org/public-portal/cross_cancer.do). 
The results showed that GD3s mRNA expression was 
inversely correlated with expression of the luminal breast 
cancer markers, ESR1, GATA3, FOXA1, MYB and XBP1 
mRNA (Figure 1A,B,C,D,E). The expression of GD3s 
mRNA was positively associated with FOXC1, which is a 
biomarker of TNBC (24) (Figure 1F). Overall, these results 
suggest that GD3s may be a potential biomarker of luminal 
breast cancer and TNBC.
Expression of GD3s in ER- breast cancers was higher than 
in ER+ breast cancers
To test the association between GD3s and ER in breast 
cancers, we did an in silico assay to compare the expression 
of GD3s in breast cancer patients with ER+ or ER- cell types 
using the Oncomine database. There was much higher 
GD3s expression in breast cancer patients that were ER- 
compared to those who were ER+ (Figure 2).
Table 2 Primers for methylation assays
Primer Forward Reverse
M GGTTTAGGAAGGAATAAATTTTCGT CCAAACTATCACCCTACTACCGT
U GGTTTAGGAAGGAATAAATTTTTGT CCAAACTATCACCCTACTACCATC
M, methylated; U, unmethylated.
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GD3s was highly expressed in TNBCs
We compared GD3s expression in TNBCs with that in 
other types of breast cancers using data from Oncomine and 
TCGA. Expression of GD3s was much higher in TNBCs 
than other types of breast cancer (Figure 3A,B,C,D,E).
To determine the levels of GD3s mRNA and protein 
expression in breast cancer cell lines, qRT-PCR and 
Western blotting were carried out. The expression of GD3s 
mRNA and protein in TNBC cells was significantly higher 
than that in other breast cancer cell lines (Figure 3F,G). 
GD3s promoted proliferation, invasion, migration and 
colony formation of breast cancer cells
To investigate the functional roles of GD3s in breast cancer, 
MCF-7 cells which normally have low GD3s expression 
were transfected with a GD3s expression plasmid. The 
MDA-MB-468 cell line, which normally has high GD3s 
expression, was transfected with GD3s shRNA that blocks 
transcription of the GD3s gene. Controls (cntl) were empty 
vector for MCF-7 and control shRNA for the MDA cell 
line. MCF-7-cntl, MCF-7-GD3s, MDA-MB-468-cntl, and 
MDA-MB-468-shRNA were tested for cell proliferation, 
migration, invasion and colony formation. Overexpression 
of GD3s promoted proliferation, invasion, migration and 
colony formation, whereas knockdown of GD3s inhibited 
these functions (Figure 4). 
GD3s expression was associated with methylation of the 
ST8SIA1 gene
To determine if GD3s expression was associated with 
methylation of the ST8SIA1 gene, in silico analysis using the 
UCSC gene browser (http://genome.ucsc.edu) was carried 
out. Results showed that there was a 102 bp CpG island in 
the promoter region of the ST8SIA1 gene (Figure 5A and 
Figure S1). Data from TCGA demonstrated that expression 
of GD3s was inversely correlated with methylation of 
Figure 1 GD3s is inversely correlated with signatures of luminal breast cancers, ESR1, FOXA1, GATA3, XBP1 and MYB. GD3s is inversely 
correlated with (A) ESR1, (B) FOXA1, (C) GATA3, (D) XBP1, and (E) MYB. GD3s is positively correlated with (F) FOXC1, which is a 
biomarker of BLBC.
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the ST8SIA1 gene (Figure 5B) and that survival rate of 
patients with breast cancers was significantly associated with 
methylation of ST8SIA1 gene (Figure 5C). Results from a 
methylation array of TCGA data (https://genome-cancer.
ucsc.edu/proj/site/hgHeatmap/) showed that there was 
significantly less methylation of ST8SIA1 gene in TCGA 
breast cancer tissues (Figure 5D). To further explore the 
association between GD3s expression and methylation of 
ST8SIA1 gene in breast cancer cells, MS-PCR was used to 
assess the methylation level in the ST8SIA1 gene promoter 
in eight breast cancer cell lines: MCF7, MDA-MB-468, 
T47D, ZR751, MDA-MB-231, BT549, MDA-MB-436, 
and HCC1143, plus a non-tumor cell line MCF-10A. The 
methylation levels of the ST8SIA1 gene promoter in the 
breast cancer cell lines were significantly lower (P<0.05) 
than in MCF-10A cells (Figure 5E). To further explore if 
ST8SIA1 gene expression was regulated by methylation, 
we treated MCF-7 cells and T47D cells, which had low 
GD3s expression, with the methyl transferase inhibitor, 
5-azacytidine, or with vehicle control (DMSO). GD3s 
expression in MCF-7 cells and T47D cells incubated 
with 5-azacytidine was increased compared to controls 
(Figure 5F). In sum, our results demonstrated that 
GD3s expression in breast cancer cells was regulated by 
methylation of ST8SIA1.
GD3s was overexpressed in TNBC tissues and associated 
with reduced OS and RFS 
IHC was performed to determine if TNBCs had greater 
GD3s protein levels than estrogen- or progesterone-
receptor-positive luminal breast cancers. Results showed 
that staining density of GD3s was significantly higher in 
TNBCs compared to luminal breast cancers (Figure 6A,B). 
To ascertain whether expression of GD3s affected the 
survival of patients with breast cancer, Kaplan Meier 
analyses were carried out. It was shown that patients with 
high GD3s had lower survival rates, while patients with low 
Figure 2 GD3s expression is significantly higher in ER+ breast cancer than ER−. (A,B,C,D,E) GD3s expression is higher in ER+ breast 
cancer than ER−. Data and statistics were obtained from www.oncomine.org (TCGA 2011; Richardson et al., 2006; Curtis et al., 2012; Gluck 
et al., 2011; Zhao et al., 2004).
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GD3s had higher survival rates (Figure 6C). Results from 
an in silico assay confirmed the survival data (Figure 6D) 
and showed that low GD3s expression was significantly 
associated with RFS of breast cancer patients (Figure S2).
Discussion
Breast cancers are commonly classified into three subtypes, 
ER+, HER2+ and TNBC (2).  TNBC has the worst 
prognosis. Up to now, there has been no drug specifically 
Figure 3 GD3s is highly expressed in TNBCs. (A,B,C,D,E) GD3s expression is higher in TNBC than other types of breast cancers. 
Data and statistics were obtained from www.oncomine.org (TCGA 2011; Richardson et al., 2006; Curtis et al., 2012; Zhao et al., 
2004; Turashvili et al., 2007); (F) GD3s mRNA expression is higher in TNBC cell lines (MDA-MB-231, MDA-MB-435 and HCC1143) 
than other types of breast cancer cell lines (MCF-7, T47D, BT47D and ZR75-1); (G) GD3s protein expression is higher in TNBC cell lines 
(MDA-MB-231, MDA-MB-435 and HCC1143) than other types of breast cancer cell lines (MCF-7, T47D, BT47D and ZR75-1).
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targeting TNBC and the molecular mechanisms controlling 
TNBC’s malignancy were unclear. Here, we reported 
that the ganglioside synthase, GD3s, was associated 
with luminal breast cancer and highly expressed in ER− 
tumors and TNBC. Expression of GD3s was regulated by 
methylation of the synthase gene, ST8SIA1 and promoted 
the proliferation, migration invasion and colony formation 
of cancer cells. In terms of survival, higher expression levels 
of GD3s were significantly associated with lower RFS and 
lower OS of breast cancer patients. 
GD2 and GD3 are highly expressed in a variety of 
malignant tumors (25). GD3s is the sole enzyme responsible 
for biosynthesis of GD3 and GD2 (20). Recent studies 
showed that GD3s was highly expressed in many cancers 
and was very important in the development of cancers 
(25,26). In this study, data from TCGA showed that GD3s 
was negatively correlated with the signatures of luminal 
breast cancers: ESR1, FOXA1, GATA3, XBP1 and MYB. 
We also found that GD3s expression was much higher in 
ER- breast cancers than in ER+ and in TNBCs compared to 
luminal breast cancers. Results from IHC showed that there 
was much higher expression of GD3s protein in patients 
Figure 4 GD3s promotes proliferation, migration, invasion and colony formation of breast cancer cells. (A) Overexpression of GD3s promotes 
proliferation of MCF-7 cells while knockdown of GD3s inhibits proliferation of MDA-MB-468; (B) overexpression of GD3s increases migration 
of MCF-7 cells while knockdown of GD3s reduces migration of MDA-MB-468; (C) overexpression of GD3s increases invasion of MCF-7 cells 
while knockdown of GD3s reduces invasion of MDA-MB-468 (stained with 1% crystal violet); (D) overexpression of GD3s promotes colony 
formation of MCF-7 cells while knockdown of GD3s inhibited colony formation of MDA-MB-468, stained with 5 mg/mL MTT. 
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with TNBC than other types of breast cancer. All these 
results suggested that GD3s was not only associated with 
ER- breast cancers but also with TNBC.
It was reported that cell migration and colony formation 
in MDA-MB-468 and MDA-MB-231 cell lines was 
reduced if expression of GD3s was knocked down by GD3s 
shRNA (27). Our results showed that GD3s over-expression 
in MCF-7 cells increased proliferation, migration, invasion 
and colony formation while knockdown of GD3s inhibited 
proliferation, invasion, migration and colony formation 
of cells in MDA-MB-468. Our results confirmed previous 
evidence in part and further suggested that GD3s played 
an important functional role in the development of breast 
cancer. Targeting GD3s inhibited proliferation and 
mobility, suggesting that GD3s may be a feasible drug 
target for breast cancer therapy, especially for TNBC.
Epigenetic regulation is an important mechanism for 
controlling gene expression and plays key roles in many 
processes of life, such as development (28,29), as well as in 
diseases like cancer (30,31). We identified a 102 bp CpG 
island in the promoter region of the ST8SIA1 gene, and 
showed that GD3s expression was inversely associated 
with methylation of the ST8SIA1 synthase gene. Further 
experiments proved that GD3s expression was increased by 
demethylation of ST8SIA1. Overexpression of GD3s caused 
by hypomethylation of ST8SIA1 promoted the development 
of breast cancer and lowered patients’ survival rates. Taken 
together, these results showed that GD3s expression was 
regulated by ST8SIA1 gene methylation and that higher 
GD3s activity was associated with development of breast 
cancers. 
TNBC patients have a poor prognosis and lower OS 
compared to patients with luminal breast cancer. This may 
be a result of GD3s over-expression that increases cell 
proliferation, migration, invasion and colony formation 
of tumor cells. Higher GD3s expression was first noted 
in patients with lower rates of OS, relapse-free survival, 
and distant metastasis-free survival of all breast cancers at 
Figure 5 GD3s expression is associated with methylation of the ST8SIA1 gene. (A) A 102 bp CpG island is present in the promoter region 
of the ST8SIA1 gene; (B) expression of GD3s is negatively correlated with methylation of ST8SIA1; (C) survival rate of patients with breast 
cancers is significantly associated with methylation of ST8SIA1; (D) methylation of ST8SIA1 is significantly lower in TCGA breast cancer 
tissues; (E) methylation levels of ST8SIA1 gene promoter in eight breast cancer cell lines are significantly lower (P<0.05) than in non-tumor 
MCF-10A cells; (F) GD3s expression in MCF-7 cells and T47D cells treated with 5-azacytidine are increased compared to controls. 
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grade 3 (Figures S3-S5). GD3s may be used as a biomarker 
for staging breast cancers and as a potential drug target in 
the future.
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Figure 6 Expression of GD3s protein is much higher in TNBC than luminal breast cancer. (A) Representative pictures of luminal (left) and triple 
negative breast cancer (right). Staining was done with diaminobenzidine and cells were counterstained with hematoxylin; (B) expression of GD3s is 
significantly higher in TNBC compared to luminal breast cancer; (C) expression of GD3s is significantly associated with overall survival (OS) in all 
patients with breast cancer; (D) expression of GD3s is significantly associated with OS in all patients with breast cancer in TCGA data.
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Supplementary
Figure S1 ST8SIA1 gene 1,000 bp promoter.
Figure S2 Expression of GD3s is significantly associated with relapse-free survival in patients with breast cancer.
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Figure S3 Expression of GD3s is significantly associated with overall survival in patients with grade 3 breast cancer.
Figure S4 Expression of GD3s is significantly associated with relapse-free survival in patients with grade 3 breast cancer.
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Figure S5 Expression of GD3s is significantly associated with distant metastasis-free survival in patients with grade 3 breast cancer.
All tumors: Subset = Grade 3
Tumors: Gene = ST8SIA1
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